Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?

Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) operates as a pharmaceutical company. It offers prescription brand, generic, and complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). With a market cap of $13.9 billion, it operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments.

Viatris has lagged behind the broader market over the past year. VTRS stock has gained 7.2% on a YTD basis and 25.2% over the past 52 weeks, compared to the S&P 500 Index’s ($SPX) 21.2% gains in 2024 and 32.7% returns over the past year.